Helsinki University Central Hospital
hus.fiLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
309
Active
69
Phase 3
13
Total enrollment
489,879
Pipeline matrix
Showing 40 of 41 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oral Antibiotics | — | — | — | — | — | 1 | |
| Mechanical Bowel Preparation | — | — | — | — | — | 1 | |
| enoxaparin or tinzaparin or dalteparin | — | — | — | — | — | 1 | |
| No intervention | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| enoxaparin/tinzaparin/dalteparin | — | — | — | — | — | 1 | |
| Hydrocortisone | — | — | — | — | — | 1 | |
| Pasireotide | — | — | — | — | — | 1 | |
| Ferric carboxymaltose | — | — | — | — | 2 | ||
| Metformin 1500 mg daily | — | — | — | — | — | 1 | |
| Metformin 2250 mg daily | — | — | — | — | — | 1 | |
| Healthy donor stool | — | — | — | — | — | 1 | |
| mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine | — | — | — | — | — | 1 | |
| Feacal microbial transplantation | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Cobimetinib | — | — | — | — | — | 1 | |
| Vismodegib | — | — | — | — | — | 1 | |
| Trastuzumab+Pertuzumab | — | — | — | — | — | 1 | |
| Entrectinib | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Vemurafenib | — | — | — | — | — | 1 | |
| Regorafenib | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Tepotinib | — | — | — | — | — | 1 | |
| Dabrafenib | — | — | — | — | — | 1 | |
| Trametinib | — | — | — | — | — | 1 | |
| Dabrafenib+Trametinib | — | — | — | — | — | 1 | |
| Pemigatinib | — | — | — | — | — | 1 | |
| Ketamine 10 mg/ml oral solution, UK special | — | — | — | — | — | 1 | |
| Cobisistat Tybost 150 mg | — | — | — | — | — | 1 | |
| Cannabidiol Epidyolex 100 mg/ml | — | — | — | — | — | 1 | |
| Fluoropyrimidine | — | — | — | — | — | 1 | |
| Pregabalin | — | — | — | — | — | 1 | |
| FMT | — | — | — | — | — | 1 | |
| Multiple daily injections of insulin | — | — | — | — | — | 1 | |
| Total neoadjuvant therapy | — | — | — | — | — | 1 |
1 more active programs hidden
Next readouts
- 2019-01
- 2021-11
- 2022-11-09
- 2024-07-31
- 2025-06-01
- 2025-12
- 2025-12
- 2026-08
- 2026-11-25
- 2026-12-31
Top conditions
- Quality of Life7
- Obesity7
- Critical Illness6
- Appendicitis5
- Surgery5
- Critically Ill4
- Spinal Cord Injuries4
- Gestational Diabetes4
Frequently asked questions about Helsinki University Central Hospital
- How many clinical trials does Helsinki University Central Hospital have on ClinicalTrials.gov?
- Helsinki University Central Hospital is listed as the lead sponsor on 309 clinical trials in ClinicalTrials.gov, 69 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Helsinki University Central Hospital's trials are in Phase 3?
- 13 of Helsinki University Central Hospital's trials are in Phase 3, spread across 41 active drug programs.
- What therapeutic areas does Helsinki University Central Hospital focus on?
- Helsinki University Central Hospital's most-studied conditions on ClinicalTrials.gov are Quality of Life, Obesity, Critical Illness, Appendicitis, Surgery.
- When are Helsinki University Central Hospital's next clinical trial readouts?
- Helsinki University Central Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications”, expected around 2019-01.